$NUVB
Nuvation Bio Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023058253 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $5.480M $7.780M $7.364M
YoY Change -25.58% -3.28% -3.19%
% of Gross Profit
Research & Development $15.35M $18.56M $9.571M
YoY Change 60.39% -12.83% -56.5%
% of Gross Profit
Depreciation & Amortization $55.00K $60.00K $49.00K
YoY Change 12.24% 7.14% 13.95%
% of Gross Profit
Operating Expenses $20.83M $26.34M $16.94M
YoY Change 23.01% -10.22% -42.8%
Operating Profit -$26.34M
YoY Change -10.22%
Interest Expense $7.067M $6.540M $3.394M
YoY Change 108.22% 237.81% 343.08%
% of Operating Profit
Other Income/Expense, Net -$23.00K $6.690M $96.00K
YoY Change -123.96% 213.35% -97.41%
Pretax Income -$13.79M -$19.65M -$20.85M
YoY Change -33.86% -27.77% -17.06%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.79M -$19.65M -$20.85M
YoY Change -33.86% -27.77% -17.06%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$0.06 -$0.09 -$0.10
COMMON SHARES
Basic Shares Outstanding 218.9M 218.9M 218.4M
Diluted Shares Outstanding 218.9K

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $611.2M $619.3M $661.0M
YoY Change -7.53% -8.1% -13.64%
Cash & Equivalents $42.65M $24.40M $101.1M
Short-Term Investments $568.6M $594.9M $559.9M
Other Short-Term Assets $1.519M $3.000M $3.819M
YoY Change -60.23% -41.11% 4.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $616.4M $625.3M $667.3M
YoY Change -7.63% -8.22% -13.57%
LONG-TERM ASSETS
Property, Plant & Equipment $717.0K $764.0K $894.0K
YoY Change -19.8% -15.3% 13.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $141.0K $100.0K $138.0K
YoY Change 2.17% -27.54% -67.22%
Other Assets $587.0K $587.0K $0.00
YoY Change
Total Long-Term Assets $5.050M $5.522M $4.823M
YoY Change 4.71% 8.27% 18.27%
TOTAL ASSETS
Total Short-Term Assets $616.4M $625.3M $667.3M
Total Long-Term Assets $5.050M $5.522M $4.823M
Total Assets $621.5M $630.9M $672.1M
YoY Change -7.54% -8.1% -13.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.209M $2.373M $2.139M
YoY Change 3.27% -20.77% -45.5%
Accrued Expenses $9.793M $11.86M $9.816M
YoY Change -0.23% 19.55% -19.12%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.97M $16.14M $13.16M
YoY Change 6.18% 15.22% -22.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.388M $3.100M $3.904M
YoY Change -38.83% -31.76% -70.49%
Total Long-Term Liabilities $2.388M $3.100M $3.904M
YoY Change -38.83% -31.76% -70.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.97M $16.14M $13.16M
Total Long-Term Liabilities $2.388M $3.100M $3.904M
Total Liabilities $16.36M $19.28M $17.07M
YoY Change -4.12% 3.92% -43.41%
SHAREHOLDERS EQUITY
Retained Earnings -$342.8M -$329.0M -$267.0M
YoY Change 28.39% 33.63% 64.0%
Common Stock $947.7M $943.9M $927.6M
YoY Change 2.17% 2.35% 1.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $605.1M $611.6M $655.1M
YoY Change
Total Liabilities & Shareholders Equity $621.5M $630.9M $672.1M
YoY Change -7.54% -8.1% -13.4%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$13.79M -$19.65M -$20.85M
YoY Change -33.86% -27.77% -17.06%
Depreciation, Depletion And Amortization $55.00K $60.00K $49.00K
YoY Change 12.24% 7.14% 13.95%
Cash From Operating Activities -$15.03M -$16.15M -$16.17M
YoY Change -7.05% -42.51% -31.14%
INVESTING ACTIVITIES
Capital Expenditures $13.00K $30.00K $65.00K
YoY Change -80.0% -129.13% -148.15%
Acquisitions
YoY Change
Other Investing Activities $33.18M -$9.570M -$21.76M
YoY Change -252.44% -114.88% -88.49%
Cash From Investing Activities $33.16M -$9.590M -$21.83M
YoY Change -251.92% -114.94% -88.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 120.0K 80.00K 407.0K
YoY Change -70.52% -68.99% -24.35%
NET CHANGE
Cash From Operating Activities -15.03M -16.15M -16.17M
Cash From Investing Activities 33.16M -9.590M -21.83M
Cash From Financing Activities 120.0K 80.00K 407.0K
Net Change In Cash 18.25M -25.66M -37.59M
YoY Change -148.56% -170.55% -82.29%
FREE CASH FLOW
Cash From Operating Activities -$15.03M -$16.15M -$16.17M
Capital Expenditures $13.00K $30.00K $65.00K
Free Cash Flow -$15.04M -$16.18M -$16.23M
YoY Change -7.34% -42.19% -30.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001811063
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39351
dei Entity Registrant Name
EntityRegistrantName
Nuvation Bio Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0862255
dei Entity Address Address Line1
EntityAddressAddressLine1
1500 Broadway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1401
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
332
dei Local Phone Number
LocalPhoneNumber
208-6102
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
218944053
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24395000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101099000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2976000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3819000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
594944000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
559915000
CY2023Q3 nuvb Interest Receivable On Marketable Securities Current
InterestReceivableOnMarketableSecuritiesCurrent
3033000
CY2022Q4 nuvb Interest Receivable On Marketable Securities Current
InterestReceivableOnMarketableSecuritiesCurrent
2485000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
625348000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
667318000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
764000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
894000
CY2023Q3 nuvb Lease Security Deposit Noncurrent
LeaseSecurityDepositNoncurrent
138000
CY2022Q4 nuvb Lease Security Deposit Noncurrent
LeaseSecurityDepositNoncurrent
138000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4033000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3791000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
587000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2023Q3 us-gaap Assets
Assets
630870000
CY2022Q4 us-gaap Assets
Assets
672141000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2373000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2139000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1915000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1206000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11855000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9816000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16143000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13161000
CY2023Q3 nuvb Warrant Liability
WarrantLiability
590000
CY2022Q4 nuvb Warrant Liability
WarrantLiability
850000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2549000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3054000
CY2023Q3 us-gaap Liabilities
Liabilities
19282000
CY2022Q4 us-gaap Liabilities
Liabilities
17065000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
218944053
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
218944053
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
218632699
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
218632699
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
943903000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
927604000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-329017000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267002000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3298000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5526000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
611588000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
655076000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
630870000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
672141000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18561000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21294000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
55938000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
70944000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7778000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8044000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23053000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24455000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
26339000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
29338000
us-gaap Operating Expenses
OperatingExpenses
78991000
us-gaap Operating Expenses
OperatingExpenses
95399000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26339000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29338000
us-gaap Operating Income Loss
OperatingIncomeLoss
-78991000
us-gaap Operating Income Loss
OperatingIncomeLoss
-95399000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
6523000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-19649000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
2127000
us-gaap Interest Income Other
InterestIncomeOther
17588000
us-gaap Interest Income Other
InterestIncomeOther
3925000
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
228000
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
263000
us-gaap Professional Fees
ProfessionalFees
689000
us-gaap Professional Fees
ProfessionalFees
647000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-383000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-462000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-260000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9866000
CY2023Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
12000
CY2022Q3 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-191000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-183000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-1099000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6690000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2135000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
16976000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12045000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19649000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27203000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62015000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83354000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-19649000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27203000
us-gaap Net Income Loss
NetIncomeLoss
-62015000
us-gaap Net Income Loss
NetIncomeLoss
-83354000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
218935
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
218935
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
218300
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
218300
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
218842
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
218842
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
216123
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
216123
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27203000
us-gaap Net Income Loss
NetIncomeLoss
-62015000
us-gaap Net Income Loss
NetIncomeLoss
-83354000
CY2023Q3 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
1097000
CY2022Q3 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-1139000
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
2228000
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-6932000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18552000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28342000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59787000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-90286000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
655076000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
298000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4837000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-21726000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2588000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
641073000
CY2023Q2 nuvb Issuance Of Common Stock For Purchase Under Espp Value
IssuanceOfCommonStockForPurchaseUnderEsppValue
133000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5523000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20640000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1457000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
624632000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
77000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5431000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-19649000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1097000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
611588000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
745997000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
314000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3577000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21293000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5032000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
723563000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
56000
CY2022Q2 nuvb Issuance Of Common Stock For Purchase Under Espp Value
IssuanceOfCommonStockForPurchaseUnderEsppValue
292000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4787000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-34858000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-761000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
693079000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
258000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2940000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-27203000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1139000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
667935000
us-gaap Profit Loss
ProfitLoss
-62015000
us-gaap Profit Loss
ProfitLoss
-83354000
us-gaap Share Based Compensation
ShareBasedCompensation
15791000
us-gaap Share Based Compensation
ShareBasedCompensation
11304000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
167000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
150000
nuvb Non Cash Lease Expense
NonCashLeaseExpense
-38000
nuvb Non Cash Lease Expense
NonCashLeaseExpense
228000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-260000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9866000
nuvb Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
8798000
nuvb Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
-4099000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-183000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-1099000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-19000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-32000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-843000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1452000
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
548000
us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-689000
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
0
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
283000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
587000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
234000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-930000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2039000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2221000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52970000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79939000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
554635000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
382598000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
530449000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
468182000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
56000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
305000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
7000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24242000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
85286000
nuvb Issuance Of Common Stock For Purchase Under Espp Value
IssuanceOfCommonStockForPurchaseUnderEsppValue
-133000
nuvb Issuance Of Common Stock For Purchase Under Espp Value
IssuanceOfCommonStockForPurchaseUnderEsppValue
-292000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
375000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
628000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
508000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
920000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-76704000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6267000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101099000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132423000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24395000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138690000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1216000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2171000
nuvb Operating Lease Liabilities Recognized
OperatingLeaseLiabilitiesRecognized
1216000
nuvb Operating Lease Liabilities Recognized
OperatingLeaseLiabilitiesRecognized
2171000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-192000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-183000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-928000
CY2023Q3 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Operations</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Nuvation Bio Inc. and subsidiaries (“Nuvation Bio”), a Delaware corporation, is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio was incorporated on March 20, 2018 (inception date) and has offices in New York and San Francisco.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 10, 2021, (the “Closing Date”), Nuvation Bio Inc., a Delaware corporation (“Legacy Nuvation Bio”), Panacea Acquisition Corp. (“Panacea”), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (“Merger Sub”) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 20, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“Merger Agreement”).</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the “Merger”) and, collectively with the other transactions described in the Merger Agreement. On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the “Company” or “Nuvation Bio”).</span></p>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-329000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53000000
CY2023Q3 nuvb Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
619300000
CY2022Q3 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Accordingly, actual results could differ from those estimates and those differences could be significant. Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, warrant liabilities, leases, stock options granted and depreciation expense.</span>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, municipal securities and exchange traded fund with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</span></p>
us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
0
CY2023Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5787472
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
us-gaap Sale Of Stock Description Of Transaction
SaleOfStockDescriptionOfTransaction
the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company’s common stock.
us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
337000
CY2022Q3 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
1000
us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
0
us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
166000
CY2023Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
0
CY2022Q3 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
1000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
0
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-171000
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
19903000
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
594944000
CY2023Q3 nuvb Total Financial Assets
TotalFinancialAssets
614847000
CY2023Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
590000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
68311000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
559915000
CY2022Q4 nuvb Total Financial Assets
TotalFinancialAssets
628226000
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
850000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
618145000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
49000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3347000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
614847000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
633752000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
86000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5612000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
628226000
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
15000
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
27000
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
9000
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
3000
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
192000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
210000
us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
937000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
12000
CY2023Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
12000
CY2022Q3 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-191000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-183000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-1099000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
453855000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
2332000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
90014000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1015000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
543869000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3347000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
253605000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1650000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
212814000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
3962000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
466419000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
5612000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
410879000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
184065000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
594944000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000
us-gaap Variable Lease Cost
VariableLeaseCost
0
us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
500000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Cost
OperatingLeaseCost
1200000
us-gaap Operating Lease Cost
OperatingLeaseCost
900000
nuvb Fair Value Equity Level1 To Level2 Or Level3 Transfers Description
FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription
no
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
529000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2172000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1416000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
629000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
81000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4827000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
363000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4464000
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0692
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y5M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.87
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5526000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1185000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
2045000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-7860000
nuvb Realized Loss On Marketable Securities
RealizedLossOnMarketableSecurities
183000
nuvb Realized Loss On Marketable Securities
RealizedLossOnMarketableSecurities
928000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3298000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8117000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5431000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2940000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15791000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11304000
CY2023Q3 us-gaap Market Risk Benefit Change In Fair Value Gain Loss
MarketRiskBenefitChangeInFairValueGainLoss
400000
us-gaap Market Risk Benefit Change In Fair Value Gain Loss
MarketRiskBenefitChangeInFairValueGainLoss
300000
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
590000
CY2022Q4 nuvb Changes In Liabilities Classified In Level3 Of Fair Value Hierarchy
ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy
37000
nuvb Change In Fair Value Of Private Warrants Liability Recognized In Earnings
ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings
-9000
CY2023Q3 nuvb Changes In Liabilities Classified In Level3 Of Fair Value Hierarchy
ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy
28000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-058253-index-headers.html Edgar Link pending
0000950170-23-058253-index.html Edgar Link pending
0000950170-23-058253.txt Edgar Link pending
0000950170-23-058253-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nuvb-20230930.htm Edgar Link pending
nuvb-20230930.xsd Edgar Link pending
nuvb-ex31_1.htm Edgar Link pending
nuvb-ex31_2.htm Edgar Link pending
nuvb-ex32_1.htm Edgar Link pending
nuvb-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
nuvb-20230930_cal.xml Edgar Link unprocessable
nuvb-20230930_def.xml Edgar Link unprocessable
nuvb-20230930_lab.xml Edgar Link unprocessable
nuvb-20230930_pre.xml Edgar Link unprocessable
nuvb-20230930_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending